Recruiting
Phase 3

Survodutide

Sponsor:

Boehringer Ingelheim

Code:

NCT07850050

Conditions

Obesity

Eligibility Criteria

Sex: Female

Age: 45 - 65

Healthy Volunteers: Not accepted

Interventions

Survodutide

Placebo

Study Details

Brief summary:

This study is open to women up to 65 years of age who are living with overweight or obesity and are going through or have finished menopause. People can join this study if they have a Body Mass Index (BMI) of 30 kg/m² or more, or if their BMI is 27 kg/m² or more and they have one or more weight related health problems. Participants must also have tried to lose weight by dieting at least once in the past without success. People with pre-existing diabetes cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps women with overweight or obesity lose weight.

Participants are put into 2 groups randomly, which means by chance. Participants have a 1 in 2 chance of receiving survodutide. One group gets survodutide as an injection under the skin. The other group gets a placebo as an injection under the skin. The placebo looks like the study medicine but does not contain any medicine. Participants take the injections once a week. All participants also receive advice on diet and physical activity.

Participants are in the study for up to 1 year and 2 months. During this time, they visit the study site about 12 times and get a few phone calls from the site staff. At the study visits, doctors regularly check participants' body weight. The results are compared between the 2 groups to see whether the treatment works. The participants fill in questionnaires about their menopause symptoms and how the symptoms affect their daily life. To assess the study endpoints, participants regularly have blood samples taken. The doctors also regularly check participants' health and take note of any unwanted effects.

Conditions

Obesity

Study ID

NCT07850050

Start date

Nov 25, 2026

Status verified date

Nov, 2026

Completion date

Jul 26, 2028

Anticipated

Primary completion date

Jul 26, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 45 - 65

Healthy Volunteers: Not accepted

Inclusion criteria:

1. Signed and dated written informed consent in accordance with International Conference of Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
2. Female (sex assigned at birth) with age >18 years at the time of screening
3. History of at least one self-reported unsuccessful dietary effort to lose body weight
4. Women of Childbearing Potential (WOCBP) must be ready and able to use at least an acceptable effective contraceptive method of birth control Further inclusion criteria apply.

Exclusion criteria:

1. Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM)
2. Glycosylated Haemoglobin A1c (HbA1c) ≥6.5% (≥48 mmol/mol) as measured by the central laboratory at screening (Visit 1)
3. Treatment with any medication for the indication of obesity within 90 days before screening
4. Body weight change (self-reported) >5% within 90 days before screening (Visit 1) Further exclusion criteria apply.

Study Design

Enrollment

600 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Survodutide arm

placebo comparator: Placebo arm

Interventions

Survodutide

Survodutide

Placebo

Placebo matching survodutide

Primary outcome measure

  • Percentage change in body weight from baseline to Week 52 [ Time Frame: At baseline and Week 52 ]

Central Contacts and Locations

Central contacts

Locations

The Center for Diabetes and Endocrine Care

Recruiting

Fort Lauderdale, Florida, United States, 33312

Contacts

Flourish Research

Recruiting

Merritt Island, Florida, United States, 32952

Contacts

West Orange Endocrinology, PA

Recruiting

Ocoee, Florida, United States, 34761

Contacts

More Information

Sponsor

Boehringer Ingelheim

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Boehringer Ingelheim on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.